Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
Read More…
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone514-484-4483
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$13.27 million
Profitability
Miscellaneous
Employees27
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Knight Therapeutics (TSE:GUD) Frequently Asked Questions
What is Knight Therapeutics' stock symbol?
Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD."
How were Knight Therapeutics' earnings last quarter?
Knight Therapeutics Inc (TSE:GUD) released its earnings results on Thursday, August, 8th. The company reported $0.13 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.02 by $0.11. The company earned $3.20 million during the quarter, compared to the consensus estimate of $3.12 million. View Knight Therapeutics' Earnings History.
When is Knight Therapeutics' next earnings date?
What price target have analysts set for GUD?
4 brokers have issued 12 month target prices for Knight Therapeutics' stock. Their predictions range from C$8.50 to C$10.25. On average, they expect Knight Therapeutics' stock price to reach C$9.58 in the next year. This suggests a possible upside of 9.6% from the stock's current price. View Analyst Price Targets for Knight Therapeutics.
What is the consensus analysts' recommendation for Knight Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Knight Therapeutics.
Has Knight Therapeutics been receiving favorable news coverage?
Media coverage about GUD stock has been trending extremely negative recently, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Knight Therapeutics earned a media sentiment score of -4.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Knight Therapeutics.
Who are some of Knight Therapeutics' key competitors?
Some companies that are related to Knight Therapeutics include Evotec (EVT), Aphria (APHA), Ecofibre (EOF), Hexo (HEXO), HEXO (HEXO), OrganiGram (OGI), Next Science (NXS), HLS Therapeutics (HLS), Green Organic Dutchman (TGOD), Supreme Cannabis (FIRE), Benchmark (BMK), Flowr (FLWR), CannTrust (TRST), ICC Labs (ICC) and Shield Therapeutics (STX).
What other stocks do shareholders of Knight Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Knight Therapeutics investors own include Constellation Software (CSU), Mondi (MNDI), Bombardier, Inc. Class B (BBD.B), Spin Master (TOY), Alimentation Couche-Tard (ATD.B), Brookfield Infrastructure Partners (BIP.UN), Canadian National Railway (CNR), Extendicare (EXE), Canopy Growth (WEED) and Allena Pharmaceuticals (ALNA).
Who are Knight Therapeutics' key executives?
Knight Therapeutics' management team includes the folowing people:
- Mr. Jonathan Ross Goodman BA, LLB, MBA, CEO & Director (Age 50)
- Ms. Samira Sakhia C.A., C.P.A., M.B.A., MBA, BCom, CPA, DPA, CA, Pres, CFO & Director (Age 50)
- Mr. Michel Loustric, Pres of Knight Barbados
- Ms. Amal Khouri, VP of Bus. Devel.
- Ms. Jody Engel, Director of Bus. Devel.
How do I buy shares of Knight Therapeutics?
Shares of GUD and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Knight Therapeutics' stock price today?
One share of GUD stock can currently be purchased for approximately C$8.74.
How big of a company is Knight Therapeutics?
What is Knight Therapeutics' official website?
How can I contact Knight Therapeutics?
The company can be reached via phone at 514-484-4483.
MarketBeat Community Rating for Knight Therapeutics (TSE GUD)
MarketBeat's community ratings are surveys of what our community members think about Knight Therapeutics and other stocks. Vote "Outperform" if you believe GUD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GUD will underperform the S&P 500 over the long term. You may vote once every thirty days.
